Moffitt Cancer Center Logo
 

Shufeng Zhou, MD, PhD

Where You Are:
Shufeng Zhou, MD, PhD

Office  (813) 974-2603

Education And Training
  • PhD, University of Auckland, 2001 - Pharmacology & Clinical Pharmacology
  • Postgraduate Diploma, Sun Yat-Sen University of Medical Sciences, 1989 - Clinical Medicine/Oncology
  • Bachelor of Medicine, Jiangxi Medical College, 1986


My research interests fall into four major categories: drug discovery, pharmacokinetics, drug metabolism and drug transport; pharmacogenetics/pharmacogenomics; nanomedicine and nanoformulation; natural products.  My studies are focused on existing and new anticancer drugs.

  • Li YC, He SM, He ZX, Li M, Yang Y, Pang JX, Zhang X, Chow K, Zhou Q, Duan W, Zhou ZW, Yang T, Huang GH, Liu A, Qiu JX, Liu JP, Zhou SF. Plumbagin induces apoptotic and autophagic cell death through inhibition of the PI3K/Akt/mTOR pathway in human non-small cell lung cancer cells. Cancer Lett. 2014 Mar;344(2):239-259. Pubmedid: 24280585.
  • Liang S, Zhou Y, Wang H, Qian Y, Ma D, Tian W, Persaud-Sharma V, Yu C, Ren Y, Zhou S, Li X. The effect of multiple single nucleotide polymorphisms in the folic Acid pathway genes on homocysteine metabolism. Biomed Res Int. 2014 Jan;2014:560183. Pubmedid: 24524080.
  • Yin JJ, Sharma S, Shumyak SP, Wang ZX, Zhou ZW, Zhang Y, Guo P, Li CZ, Kanwar JR, Yang T, Mohapatra SS, Liu W, Duan W, Wang JC, Li Q, Zhang X, Tan J, Jia L, Liang J, Wei MQ, Li X, Zhou SF. Synthesis and Biological Evaluation of Novel Folic Acid Receptor-Targeted, β-Cyclodextrin-Based Drug Complexes for Cancer Treatment. PLoS One. 2013;8(5):e62289. Pubmedid: 23658721.
  • Zhou S. Correspondence re: J. Lu et al., thalidomide metabolites in mice and patients with multiple myeloma. Clin. Cancer Res., 9: 1680-1688, 2003. Clin Cancer Res. 2003 Nov;9(14):5429. Pubmedid: 14614031.
TOOLS:   Font Size small font resizer separator font resizer separator big font resizer